Publications by authors named "J V Talano"
We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent αβ-T-cell/CD19-depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to rabbit antithymocyte globulin (rATG; Thymoglobulin). Between 2015 and 2023, 163 patients with a median age of 13 years (range, 0.4-27.
View Article and Find Full Text PDFBackground: Due to the risk of cerebral vascular injury, children and adolescents with high-risk sickle cell disease (SCD) experience neurocognitive decline over time. Haploidentical stem cell transplantation (HISCT) from human leukocyte antigen-matched sibling donors may slow or stop progression of neurocognitive changes.
Objectives: The study is to determine if HISCT can ameliorate SCD-associated neurocognitive changes and prevent neurocognitive progression, determine which specific areas of neurocognitive functioning are particularly vulnerable to SCD, and determine if there are age-related differences in neurocognitive functioning over time.
Primary hemophagocytic lymphohistiocytosis (pHLH) is a life-threatening hyperinflammatory syndrome that develops mainly in patients with genetic disorders of lymphocyte cytotoxicity and X-linked lymphoproliferative syndromes. Previous studies with etoposide-based treatment followed by hematopoetic stem cell transplantation (HSCT) resulted in 5-year survival of 50% to 59%. Contemporary data are lacking.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the use of mediports for administering CAR T cell therapy in patients with B-cell malignancies, aiming to establish standardized practices in this area due to previous concerns about effectiveness and safety.
- Data was collected from 34 medical centers, analyzing 504 CAR T cell infusions, making it one of the largest reports on this topic since CAR T cell commercialization began in 2017.
- Results showed that 85% of centers accepted mediports as standard practice, with no incidents of CAR T cell infiltration reported among the 184 patients infused via mediports, supporting their safe use in clinical settings.